Mesenchymal Stem Cell Treatment Clinical Observation For The Optic Nerve Injury

Purpose Observe the safety and curative effect of mesenchymal stem cell therapy for optic nerve injury (ONI).Methods Use MEM as culture medium, by the lymphocyte separation liquid indirect separation, separate mesenchymal stem cells (MSCs) by adherent culture for primary culture and purification. Observe cell growth state and morphological changes under inverted microscope, and observe immunohistochemical stains appraisal of cell surface antigen CD34, CD44, CD29, isolate mesenchymal stem cells by focusing microscope. Collected in December 2010 to September 2011 ONI to our hospital 23 patients in our hospital between Dec 2010 and Sep 2011,15 male and 8 female, between 5 and 77 years, and average age was 30.1 years old, with 12 primary optic nerve atrophy (ON A) patients,5 Leber Hereditary Optic Neuropathy (LHON) patients,1 Optic Nerve Hypoplasia (ONH) patient,2 Septo Optic Dysplasia (SOD) patients, and 3 Retinitis Pigmentosa (RP) patients. We detected every indicator before and after treatments, included ALT, AST, BUN, creatinine, blood sugar, TG, cholesterol, HBsAg, PT, partial thromboplastin time (APIT), AFP, CEA and ophthalmologic examination:visual acuity(VA), intraocular pressure(IOP), cup to disk ratio. Using isolated stem cells treated for collected 23 optic nerve injury patients in 4 treatments, each treatment gave 2-4×10'stem-cells apart 3 to 5 days. By comparing the Flash visual evoked potential(F-VEP)results before and after treatments for ONI patients, analyse the treatment effect of MSCs.Result Strong expression of CD44, and no expression CD34 under fluorescent microscope are. Show that MSCs express mesenchymal cells surface antigen and do not express hematopoietic cells, progenitor cells or endothelial cell surface antigen. It was accordant with bone marrow-derived MSCs immunohistochemical results. There was no significant difference in laboratory indicators, IOP and cup to disk ratio, however, there were marked difference in VA, latency and amplitude of F-VEP before and after treatments. Conclusion Succeed in obtaining mesenchymal stem cells. The procedure of mesenchymal stem-cells treatment for ONI patients is safe and reliable. Mesenchymal stem-cells transplantation is able to improve ONI patients'VA, F-VEP.